Company Update

Summary by AI BETAClose X

Wellnex Life Limited is exploring various financing solutions, including unsolicited preliminary interest from parties regarding the acquisition of Pain Away and other assets, with early-stage due diligence underway. Additionally, a syndicate has proposed convertible note funding to expand Pain Away internationally. The company is actively assessing these opportunities alongside traditional debt and equity options to optimize its capital structure, settle former director loan repayments due in April 2026, and drive business turnaround.

Disclaimer*

Wellnex Life Limited
09 February 2026
 

                                                                       

ASX/AIM Announcement                                                                                  9 February 2026

 

 

Company Update

 

Wellnex Life Limited (ASX/AIM: WNX) ("Wellnex Life" or the "Company")

Further to the Company's recent market update announcing significant improvement in H1 EBITDA and gross margin, confirming the turnaround trajectory remains on track, the Board provides the following update regarding various financing solutions under consideration.

The Company has received unsolicited preliminary interest from separate parties regarding the acquisition of Pain Away and other assets. Early-stage due diligence is underway across both approaches.

Additionally, a syndicate has approached the Company with an indicative early-stage proposal to provide convertible note funding to expand Pain Away into Asia and North America, aligned with the Company's strategy of delivering positive free cash flow, profitability and long-term shareholder value.

 

Financing Evaluation

The Board is actively assessing these opportunities alongside traditional debt and equity options to secure the optimal capital structure to maximise value for all shareholders, to settle former director loan repayments due in April 2026 and to drive the turnaround in the business and Pain Away brand.  

 

The Company will provide further updates in accordance with its continuous disclosure obligations under ASX Listing Rules and AIM Regulation. There can be no certainty that any or all of the potential transactions outlined above will proceed to completion or as to the terms of any transaction Any potential transaction will be assessed against applicable regulatory requirements.

 

--- END ---

For further information, please contact:

Wellnex Life Limited (ASX/AIM:WNX)                             Reach Markets

Ash Vesali                                                                             T: 1300 805 941

Executive Chairman                                                           E: IR@reachmarkets.com.au

E: ash.v@wellnexlife.com.au

 

UK Investors

Strand Hanson (Financial & Nominated Advisor)

 

James Harris / Richard Johnson                                      Tel: +44 (0) 20 7409 3494

 

Orana Corporate LLP (Joint Broker)                                                swykeham@oranacorp.com

Sebastian Wykeham    

 

S.P. Angel Corporate Finance LLP (Joint Broker)        Tel: +44 (0)20 3470 0470

David Hignell / Vadim Alexandre

 

To learn more, please visit: https://wellnexlife.com.au/

The information contained within this announcement is deemed by the Company to constitute inside information pursuant to article 7 of EU Regulation 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 as amended.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings